- Home
- RRGB vs ENTX Comparison
RRGB vs ENTX Comparison
Compare RRGB & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- ENTX
- Stock Information
- Founded
- RRGB 1969
- ENTX 2010
- Country
- RRGB United States
- ENTX Israel
- Employees
- RRGB N/A
- ENTX N/A
- Industry
- RRGB Restaurants
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RRGB Consumer Discretionary
- ENTX Health Care
- Exchange
- RRGB Nasdaq
- ENTX Nasdaq
- Market Cap
- RRGB 88.7M
- ENTX 82.2M
- IPO Year
- RRGB 2002
- ENTX 2018
- Fundamental
- Price
- RRGB $6.98
- ENTX $1.91
- Analyst Decision
- RRGB Strong Buy
- ENTX Strong Buy
- Analyst Count
- RRGB 2
- ENTX 1
- Target Price
- RRGB $11.00
- ENTX $10.00
- AVG Volume (30 Days)
- RRGB 238.9K
- ENTX 50.8K
- Earning Date
- RRGB 11-05-2025
- ENTX 11-07-2025
- Dividend Yield
- RRGB N/A
- ENTX N/A
- EPS Growth
- RRGB N/A
- ENTX N/A
- EPS
- RRGB N/A
- ENTX N/A
- Revenue
- RRGB $1,235,920,000.00
- ENTX $166,000.00
- Revenue This Year
- RRGB N/A
- ENTX N/A
- Revenue Next Year
- RRGB N/A
- ENTX N/A
- P/E Ratio
- RRGB N/A
- ENTX N/A
- Revenue Growth
- RRGB N/A
- ENTX 191.23
- 52 Week Low
- RRGB $2.50
- ENTX $1.50
- 52 Week High
- RRGB $7.89
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- RRGB 54.52
- ENTX 53.16
- Support Level
- RRGB $6.77
- ENTX $1.84
- Resistance Level
- RRGB $7.52
- ENTX $1.93
- Average True Range (ATR)
- RRGB 0.36
- ENTX 0.08
- MACD
- RRGB -0.01
- ENTX 0.01
- Stochastic Oscillator
- RRGB 55.04
- ENTX 68.18
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. The company has one operating and one reportable segment: restaurants.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.